Apolipoprotein B (ApoB)

The anchor. No supplement, diet, or other drug comes close, and statins carry more hard-outcome data than anything else in medicine — each 1 mmol/L of LDL lowering cuts major vascular events by roughly a fifth, replicated across 26 trials and ~170,000 people.¹²¹¹ Worth it if your number is high (100+) or your overall risk is meaningful and lifestyle isn’t enough. Don’t fear it by default — it’s the most road-tested tool on this page.

The direct ApoB move is modest, but the outcome data is the best of any diet: PREDIMED found ~30% fewer major cardiovascular events versus a low-fat control.¹⁵ Swap butter, fatty red meat, and full-fat dairy for olive oil, fish, nuts, and beans. This is the foundation the rest stacks on — for basically everyone.

The strongest direct ApoB effect any diet has in the trial record — a meta-analysis found plant-based patterns drop ApoB by about 13 mg/dL versus omnivore eating (the ApoB result came from 6 of its 30 trials).¹⁴ The “Portfolio” version stacks sterols, soy, viscous fiber, and nuts. More work than “eat Mediterranean,” but if you’re motivated to avoid meds, this is the diet to beat. Adherence is the whole game.

Roughly 1% ApoB drop per 1% of body weight lost, concentrated in visceral fat — it dials down the triglyceride-and-VLDL pathway that pumps out particles. In a Look AHEAD analysis, people who lost ≥10% of their body weight in the first year had about 21% fewer cardiovascular events.¹⁶ Worth it if you’re overweight, especially with metabolic syndrome. The failure mode is maintenance, not the losing.

The gentle, well-tolerated add-on. On its own it drops ApoB ~13–20%; bolted onto a statin, another ~10–15% — and IMPROVE-IT proved it cuts events on top of a statin after a heart attack, the first non-statin LDL drug to do so.¹⁷ Worth it if a statin alone didn’t get you to target. An easy yes.

A spoon of psyllium husk before meals forms a gel that drags cholesterol out with it. A 28-trial meta-analysis put the ApoB drop near 5 mg/dL with GRADE-high certainty on that exact endpoint.¹⁸ Cheap, OTC, near-zero downside, constipation co-benefit. Best effort-to-payoff ratio on the page.

2 g/day (fortified spreads or supplements) cuts LDL-C ~8%, replicated across 124 trials; ApoB is expected to fall in step, though that meta-analysis reported LDL-C rather than ApoB directly.¹⁹ A low-effort, well-established add-on with unimpeachable safety — just no hard-outcome trial.

Built for the statin-intolerant. CLEAR Outcomes cut major events 13%.²⁰ Evidence stays B (not A) because it rests on that single landmark trial — our bar for A is replication. Watch uric acid (gout risk). Worth it if you genuinely can’t take statins and need more than diet.

The biggest ApoB drop available, with two independent outcome trials behind it — FOURIER and ODYSSEY OUTCOMES — the best evidence on the page.²¹²² It’s Tier B purely for the ~$6,000/yr price and the injections. Worth it if you’re high-risk, have familial hypercholesterolemia, or can’t tolerate statins — and can get it covered.

Same target as PCSK9 drugs but an siRNA — a shot just twice a year, which solves the adherence problem.²³ The catch: its cardiovascular-outcome trial (ORION-4) hasn’t reported yet, with completion estimated mid-2026,²⁴ so the biomarker case is strong but the outcomes case isn’t proven. Worth it if you need deep lowering and value not injecting monthly.

Mostly a weight-loss effect routed through a drug. SELECT showed a 20% drop in major events in overweight adults without diabetes.²⁵ Worth it if you’re overweight with elevated ApoB — but you’re taking it for the weight, and the ApoB improvement comes along for the ride. (~$1,000+/month branded.)

The teaching case: tiny biomarker move, large outcome win — REDUCE-IT cut events 25% on top of a statin.²⁶ The benefit isn’t coming from the ApoB drop (and the trial’s mineral-oil comparator is a recognized controversy). Worth it if you’re on a statin with stubbornly high triglycerides (135–499). Niche, but real.

Long-term mortality data is excellent — the Swedish Obese Subjects study found ~29% lower all-cause mortality a decade out.²⁷ Tier B for the obvious effort-and-risk reason, not the evidence. Worth it if you already meet the criteria (BMI ≥35 with metabolic disease) — not a first-line ApoB move.

Read this one carefully, because the community gets it wrong. The longevity crowd treats cardio as a major ApoB lever. It isn’t — directly. A 57-trial meta-analysis found it moves ApoB by about 2 mg/dL, not even statistically significant overall.²⁸ Exercise is fantastic for your heart, insulin sensitivity, and weight (which then lowers ApoB) — so absolutely do it. Just don’t expect cardio alone to fix a high number.

Real biomarker movement, but the modern outcome trials (FIELD, ACCORD-Lipid) missed their primary endpoints,²⁹ and the related drug pemafibrate cut triglycerides yet failed to reduce events in PROMINENT.³⁰ Worth it only in the narrow high-triglyceride, low-HDL niche with a doctor steering — otherwise skip.

Honest truth: this is a statin — it contains lovastatin (monacolin K), just at an unregulated dose that can vary ~100-fold between bottles.³² It’s not a gentler natural alternative; it’s a statin you can’t dose properly. If you need a statin’s effect, take an actual statin.

A modest signal in metabolic-syndrome populations, but the ApoB-specific data is thin and the trial base is mostly small, lower-quality studies.³³ Fine as an adjunct with realistic expectations — not a primary lever.

The cautionary tale. It lowers ApoB nicely on paper — but two large modern trials found zero reduction in events on top of a statin, plus real harms: new diabetes, bleeding, infection, miserable flushing.³¹ The number moved; the outcomes didn’t. Not recommended. Proof that moving the marker isn’t the goal — preventing events is.